Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

The country is also advancing the integration of TCM into modern healthcare by optimizing its clinical use and expanding ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of ...

Parkinson's disease patients and advocates are marking Friday as the start of a new era for treatment of the illness as a ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...